Disease progression and pharmacological intervention in a nutrient-deficient rat model of nonalcoholic steatohepatitis
Digestive Diseases and Sciences 64(5):1238-1256, 2019
Novel GLP-1/GLP-2 co-agonists display marked effects on gut volume and improves glycemic control in mice
Physiology and Behavior 192:72-81, 2018
Metabolic and hepatic effects of liraglutide, obeticholic acid and elafbranor in diet-induced obese mouse models of biopsy-confrmed nonalcoholic steatohepatitis
World Journal of Gastroenterology 24(2):179–194, 2018
INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis
World Journal of Gastroenterology 24(2):195–210, 2018
GUB06-046, a novel secretin/glucagon-like peptide 1 co-agonist, decreases food intake, improves glycemic control, and preserves beta cell mass in diabetic mice
Journal of Peptide Science 23(12):845–854, 2017
In-vitro and in-vivo studies supporting the therapeutic potential of ZP3022 in diabetes
European Journal of Pharmacology 815:181–189, 2017
Peptide Half-Life Extension: Divalent, Small-Molecule Albumin Interactions Direct the Systemic Properties of Glucagon-Like Peptide 1 (GLP-1) Analogues
Journal of Medicinal Chemistry 60(17):7434–7446, 2017
A hydrogel-microsphere drug delivery system that supports once-monthly administration of a GLP-1 receptor agonist
ACS Chemical Biology 12(8):2107–2116, 2017